- Home
- UNCY vs ATRA Comparison
UNCY vs ATRA Comparison
Compare UNCY & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- ATRA
- Stock Information
- Founded
- UNCY 2016
- ATRA 2012
- Country
- UNCY United States
- ATRA United States
- Employees
- UNCY N/A
- ATRA N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNCY Health Care
- ATRA Health Care
- Exchange
- UNCY Nasdaq
- ATRA Nasdaq
- Market Cap
- UNCY 74.2M
- ATRA 67.9M
- IPO Year
- UNCY 2021
- ATRA 2014
- Fundamental
- Price
- UNCY $4.36
- ATRA $12.91
- Analyst Decision
- UNCY Strong Buy
- ATRA Strong Buy
- Analyst Count
- UNCY 4
- ATRA 3
- Target Price
- UNCY $63.75
- ATRA $21.00
- AVG Volume (30 Days)
- UNCY 483.3K
- ATRA 57.1K
- Earning Date
- UNCY 08-14-2025
- ATRA 08-11-2025
- Dividend Yield
- UNCY N/A
- ATRA N/A
- EPS Growth
- UNCY N/A
- ATRA N/A
- EPS
- UNCY N/A
- ATRA 0.56
- Revenue
- UNCY N/A
- ATRA $188,667,000.00
- Revenue This Year
- UNCY N/A
- ATRA N/A
- Revenue Next Year
- UNCY $3,131.28
- ATRA N/A
- P/E Ratio
- UNCY N/A
- ATRA $22.92
- Revenue Growth
- UNCY N/A
- ATRA 202.41
- 52 Week Low
- UNCY $3.24
- ATRA $5.01
- 52 Week High
- UNCY $11.00
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- UNCY 49.39
- ATRA 62.74
- Support Level
- UNCY $4.15
- ATRA $11.70
- Resistance Level
- UNCY $4.35
- ATRA $12.76
- Average True Range (ATR)
- UNCY 0.24
- ATRA 0.75
- MACD
- UNCY 0.05
- ATRA 0.02
- Stochastic Oscillator
- UNCY 53.76
- ATRA 85.50
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).